Robert E. Abernathy
Known title: DirectorCIK: 0001222888
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Haemonetics Gets Price Target Hikes Amid Recent Stock Jump. Barrington Research and Mizuho both raised their price targets for Haemonetics to $140, maintaining Outperform ratings. This follows a recent 17.5% jump in the stock, which is now trading near its 52-week high. While some analysts note the current price may not be an ideal entry point, the firm's outlook has improved due to CSL Plasma developments.
Transaction History
| AVNT | ▲ Buy | Grant | 958 | $0 | 9/30/2026 | View on chart |
| HAE | ▲ Buy | Grant | 2,538 | — | 7/24/2026 | View on chart |
| AVNT | ▲ Buy | Grant | 1,049 | $0 | 6/30/2026 | View on chart |
| AVNT | ▲ Buy | Grant | 1,072 | $0 | 3/31/2026 | View on chart |
| AVNT | ▲ Buy | Grant | 1,239 | $0 | 12/31/2025 | View on chart |
| AVNT | ▲ Buy | Grant | 1,192 | $0 | 9/30/2025 | View on chart |
| HAE | ▲ Buy | Grant | 2,693 | — | 7/24/2025 | View on chart |
| AVNT | ▲ Buy | Grant | 1,187 | $0 | 6/30/2025 | View on chart |
| AVNT | ▲ Buy | Grant | 1,055 | $0 | 3/31/2025 | View on chart |
| AVNT | ▲ Buy | Grant | 955 | $0 | 12/31/2024 | View on chart |
| AVNT | ▲ Buy | Grant | 775 | $0 | 9/30/2024 | View on chart |
| HAE | ▲ Buy | Grant | 2,207 | — | 7/25/2024 | View on chart |
| AVNT | ▲ Buy | Grant | 806 | $0 | 6/28/2024 | View on chart |
| AVNT | ▲ Buy | Grant | 808 | $0 | 3/29/2024 | View on chart |
| AVNT | ▲ Buy | Grant | 1,040 | $0 | 12/31/2023 | View on chart |
| AVNT | ▲ Buy | Grant | 834 | $0 | 12/29/2023 | View on chart |
| AVNT | ▲ Buy | Grant | 984 | $0 | 9/29/2023 | View on chart |
| HAE | ▲ Buy | Grant | 2,226 | — | 8/4/2023 | View on chart |
| AVNT | ▲ Buy | Grant | 863 | $0 | 6/30/2023 | View on chart |
| AVNT | ▲ Buy | Grant | 857 | $0 | 3/31/2023 | View on chart |
| AVNT | ▲ Buy | Grant | 1,139 | $0 | 9/30/2022 | View on chart |
| HAE | ▲ Buy | Grant | 2,730 | — | 8/5/2022 | View on chart |
| AVNT | ▲ Buy | Grant | 880 | $0 | 6/30/2022 | View on chart |
| AVNT | ▲ Buy | Grant | 717 | $0 | 3/31/2022 | View on chart |
| AVNT | ▲ Buy | Grant | 627 | $0 | 12/31/2021 | View on chart |
| AVNT | ▲ Buy | Grant | 744 | $0 | 9/30/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
Avient Announces New CEO Mike Frank, Reaffirms Guidance
Avient disclosed that Mike Frank will assume the chief executive role, succeeding Dr. Ashish Khandpur. The company kept its FY2026 adjusted EPS outlook of $3.10‑$3.25 and its Q3 adjusted EPS guidance of $0.80. The leadership change was highlighted alongside a dividend champion note, and the stock fell about 7% after the news. The announcement arrives as the shares trade near a long‑standing support level.
Avient Announces New CEO Mike Frank, Reaffirms Guidance. Avient disclosed that Mike Frank will assume the chief executive role, succeeding Dr. Ashish Khandpur. The company kept its FY2026 adjusted EPS outlook of $3.10‑$3.25 and its Q3 adjusted EPS guidance of $0.80. The leadership change was highlighted alongside a dividend champion note, and the stock fell about 7% after the news. The announcement arrives as the shares trade near a long‑standing support level.